Lindbrook Capital LLC Grows Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Lindbrook Capital LLC lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 290.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,620 shares of the company’s stock after buying an additional 1,205 shares during the quarter. Lindbrook Capital LLC’s holdings in TransMedics Group were worth $101,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMDX. Principal Financial Group Inc. grew its position in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. State of Michigan Retirement System bought a new position in TransMedics Group in the 4th quarter worth about $6,734,000. Public Sector Pension Investment Board bought a new position in TransMedics Group in the 3rd quarter worth about $11,079,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after purchasing an additional 64,872 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

TMDX opened at $67.46 on Friday. The company’s 50-day simple moving average is $68.30 and its two-hundred day simple moving average is $98.19. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.27 billion, a P/E ratio of 71.77 and a beta of 2.12.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Robert W. Baird dropped their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. TD Cowen dropped their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Piper Sandler dropped their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.